[go: up one dir, main page]

NO20071330L - Enzyminhibitor i leukemi - Google Patents

Enzyminhibitor i leukemi

Info

Publication number
NO20071330L
NO20071330L NO20071330A NO20071330A NO20071330L NO 20071330 L NO20071330 L NO 20071330L NO 20071330 A NO20071330 A NO 20071330A NO 20071330 A NO20071330 A NO 20071330A NO 20071330 L NO20071330 L NO 20071330L
Authority
NO
Norway
Prior art keywords
leukemia
enzyme inhibitor
treatment
aml
medicament
Prior art date
Application number
NO20071330A
Other languages
English (en)
Inventor
Tsvee Lapidot
Sigal Tavor
Isabelle Petit
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20071330L publication Critical patent/NO20071330L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G01N33/57505—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Oppfinnelsen angår anvendelse av en elastaseinhibitor til fremstilling av et medikament for behandling av leukemi, fortrirmsvis akutt leukemi og mer fortrirmsvis behandling av AML.
NO20071330A 2004-08-10 2007-03-12 Enzyminhibitor i leukemi NO20071330L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL163453A IL163453A0 (en) 2004-08-10 2004-08-10 Enzyme inhibitor in leukemia
PCT/IL2005/000840 WO2006016353A2 (en) 2004-08-10 2005-08-04 Elastase inhibitor in leukemia

Publications (1)

Publication Number Publication Date
NO20071330L true NO20071330L (no) 2007-03-12

Family

ID=35124397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071330A NO20071330L (no) 2004-08-10 2007-03-12 Enzyminhibitor i leukemi

Country Status (10)

Country Link
US (1) US20090232793A1 (no)
EP (1) EP1781377B1 (no)
JP (1) JP4950885B2 (no)
AT (1) ATE552888T1 (no)
AU (1) AU2005270821B2 (no)
CA (1) CA2576419C (no)
ES (1) ES2381195T3 (no)
IL (2) IL163453A0 (no)
NO (1) NO20071330L (no)
WO (1) WO2006016353A2 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148924A (en) * 2002-03-26 2015-06-30 Mor Research Applic Ltd Use of substances that inhibit intracellular elastase activity in the preparation of a drug for the treatment and / or prevention of necrosis of cells and related diseases
WO2017049002A1 (en) * 2015-09-15 2017-03-23 Massachusetts Institute Of Technology A humanized mouse model of de novo human acute myeloid leukemia with a matching human immune system
CN116087338B (zh) * 2023-04-10 2023-07-14 四川省地质矿产勘查开发局一0六地质队 一种岩石脆性破坏前兆指标的构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2656944B2 (ja) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
GB9307555D0 (en) 1992-04-16 1993-06-02 Zeneca Ltd Heterocyclic compounds
WO1997039028A1 (en) * 1996-04-12 1997-10-23 American National Red Cross Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof
US5760027A (en) * 1996-12-06 1998-06-02 Research Corporation Technologies, Inc. Use of 7-alkylidene cephalosporins to inhibit elastase activity
GB9719172D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
CA2448253A1 (en) * 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
IL148924A (en) 2002-03-26 2015-06-30 Mor Research Applic Ltd Use of substances that inhibit intracellular elastase activity in the preparation of a drug for the treatment and / or prevention of necrosis of cells and related diseases
AU2003299526A1 (en) * 2002-06-14 2004-06-07 North Shore - Long Island Jewish Research Institute Novel human elastases and stress urinary incontinence

Also Published As

Publication number Publication date
WO2006016353A3 (en) 2006-07-13
CA2576419C (en) 2013-07-02
JP2008509903A (ja) 2008-04-03
IL163453A0 (en) 2009-02-11
EP1781377A2 (en) 2007-05-09
IL181183A (en) 2010-12-30
IL181183A0 (en) 2007-07-04
ATE552888T1 (de) 2012-04-15
CA2576419A1 (en) 2006-02-16
ES2381195T3 (es) 2012-05-24
EP1781377B1 (en) 2012-04-11
JP4950885B2 (ja) 2012-06-13
WO2006016353A2 (en) 2006-02-16
AU2005270821B2 (en) 2011-06-02
AU2005270821A1 (en) 2006-02-16
US20090232793A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
NO20070608L (no) Anvendelse av 2-tio-3,5-dicyano-4-fenyl-6-aminopyridiner ved behandling av kvalme og oppkast
PL1789390T3 (pl) Pirydylowe inhibitory szlaku sygnałowego hedgehog
HN2003000227A (es) Inhibidores de quinasas
EA200700717A1 (ru) Сульфонамиды
TW200510397A (en) Conjugated complement cascade inhibitors
ATE424159T1 (de) Katheter
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
DE602004010206D1 (de) Dipeptidyl Peptidase Inhibitoren.
NO20053041D0 (no) Behandling av diabetes.
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EA200870019A1 (ru) Лактамовые соединения и способы их применения
NO20052058D0 (no) Behandling av influensa.
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
BRPI0511615B8 (pt) forma de administração oral compreendendo bactéria probiótica
ATE529531T1 (de) Gm3-synthase als therapeutisches ziel bei mikrovaskulären komplikationen des diabetes
CR7758S (es) Barra de caramelo (paloma)
MX2007007613A (es) Formulaciones farmaceuticas.
TW200722427A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
SE0302304D0 (sv) Novel compounds
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
WO2007047608A3 (en) Fibrin targeted therapeutics
DE602004028493D1 (de) Isochinolinon-kaliumkanalinhibitoren
WO2005097103A3 (en) Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors
NO20071330L (no) Enzyminhibitor i leukemi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application